<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00113555</url>
  </required_header>
  <id_info>
    <org_study_id>URM01-01-01</org_study_id>
    <nct_id>NCT00113555</nct_id>
  </id_info>
  <brief_title>Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence</brief_title>
  <acronym>ACT</acronym>
  <official_title>Clinical Investigation of an Adjustable Continence Therapy (ACT) Periurethral Prosthetic System for Treatment of Female Stress Urinary Incontinence With or Without Hypermobility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uromedica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uromedica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of a minimally invasive
      surgical procedure in up to 160 implanted female patients in which two adjustable balloons
      (one on each side of the urethra) are implanted to treat urinary stress incontinence.

      The results will be analyzed to demonstrate the effects of the device as well as its
      associated risks. Therapeutic success will be based on whether the patients demonstrate at
      least a one-grade (mean) reduction in the Stamey score at 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, non randomized clinical trial comparing baseline data to
      the 12 month data. Urodynamic testing, pad weights and a direct visual stress test will be
      used to determine success along with the Stamey score.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Stamey Grade From Baseline to 12 Months.</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>The Stamey grade classifies the severity of stress incontinence in four possible grades from 0-3. Grade 0: no leaking, Grade 1: loss of urine with sudden increases of abdominal pressure: e.g. coughing, sneezing or laughing, Grade 2: loss of urine with lesser degrees of stress: e.g. walking or standing up, and Grade 3: loss of urine without any relation to physical activity or position, e.g. while lying in bed.
The primary end point at 12 months is a mean change in Stamey Grade from baseline of greater than or equal to -1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incontinence Quality of Life (IQoL) Questionnaire</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change on Incontinence Quality of Life (IQoL) Questionnaire from baseline to 12 months. 0 being lowest quality of life, 100 being highest quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence Impact Questionnaire (IIQ-7)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Incontinence Impact Questionnaire (IIQ-7) change from baseline to 12 months. Scores range from 0-100. 0 being impact from incontinence, 100 being most impacted from incontinence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Distress Inventory (UDI-6)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change on Urinary Distress Inventory (UDI-6) questionnaire from baseline to 12 months. 0 being not distressed, 100 being very distressed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incontinence Episodes Per Day (Voiding Diary)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in Number of Incontinence Episodes Per Day from baseline to 12 months. 0 being the best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Pads Changed Per Day (Voiding Diary)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in Number of Pads Changed Per Day from baseline to 12 months. 0 pads changed a day being the best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provocative Pad Weight</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in weight of pads (gm) from baseline to 12 months. 0 gm pad weight being the best.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label Study, ACT (Adjustable Continence Therapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACT (Adjustable Continence Therapy)</intervention_name>
    <description>surgically implanted device</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women

          -  18 years or older

          -  Diagnosed with stress urinary incontinence with or without urethral hypermobility

          -  Willing to sign informed consent

          -  Candidates for surgical intervention for stress incontinence

          -  Negative urinalysis or urine culture within 2 weeks of implantation

          -  Normal cystourethroscopy

          -  Failed at least 6 months of previous treatments for stress urinary incontinence (e.g.,
             exercise regimen, electrical stimulation, surgical procedures, etc.)

          -  May have failed suspension or sling procedures

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Life expectancy of less than one year

          -  Insulin dependant diabetic

          -  Auto-immune disease

          -  Undergoing radiation therapy

          -  Active urinary tract infection

          -  Detrusor instability refractory to meds

          -  Reduced bladder compliance

          -  Significant bladder residual &gt;100mls

          -  Bladder cancer

          -  Unsuccessfully treated bladder stones

          -  Current urethral stricture preventing the passage of a 24 French endoscope

          -  Neurogenic bladder

          -  Uncorrected rectocele, cystocele, urethrocele, enterocele or pelvic prolapse of Grade
             3 or higher

          -  Prior pelvic radiotherapy

          -  Artificial urinary sphincter implanted
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Cook</last_name>
    <role>Study Director</role>
    <affiliation>Uromedica, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Urology</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Urology Care</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research Inc.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T5GI</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS-Fleurimont</name>
      <address>
        <city>Fleurimont</city>
        <state>Quebec</state>
        <zip>J1H5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 8, 2005</study_first_submitted>
  <study_first_submitted_qc>June 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2005</study_first_posted>
  <results_first_submitted>January 4, 2016</results_first_submitted>
  <results_first_submitted_qc>April 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2018</results_first_posted>
  <last_update_submitted>July 5, 2018</last_update_submitted>
  <last_update_submitted_qc>July 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urinary incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 10 investigational sites in US and 2 in Canada which were clinics,University hospitals or Research centers implanted patients in this study from the period 2001-2006.A total of 221 patients have been enrolled(218 with enrollment data) and 163 of those patients underwent an implant procedure.</recruitment_details>
      <pre_assignment_details>One patient was implanted and was considered a compassionate use patient that did not meet the enrollment criteria.This patient was not included in the efficacy and safety summaries and her adverse vents are recorded.Therefore the total number of implants for the analyses is 162.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACT Adjustable Continence Therapy for Women</title>
          <description>Open Label Study, patients implanted with ACT device for treatment of Stress Urinary Incontinence</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED</title>
              <participants_list>
                <participants group_id="P1" count="162">1 Additional Patient was treated on a compassionate use basis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142">All treated patients were considered in the Intent to Treat analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Baseline Failure</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Permanently Explanted</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Followup</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>Open Label Study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.6" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Stamey Grade From Baseline to 12 Months.</title>
        <description>The Stamey grade classifies the severity of stress incontinence in four possible grades from 0-3. Grade 0: no leaking, Grade 1: loss of urine with sudden increases of abdominal pressure: e.g. coughing, sneezing or laughing, Grade 2: loss of urine with lesser degrees of stress: e.g. walking or standing up, and Grade 3: loss of urine without any relation to physical activity or position, e.g. while lying in bed.
The primary end point at 12 months is a mean change in Stamey Grade from baseline of greater than or equal to -1.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Open Label Study</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Stamey Grade From Baseline to 12 Months.</title>
          <description>The Stamey grade classifies the severity of stress incontinence in four possible grades from 0-3. Grade 0: no leaking, Grade 1: loss of urine with sudden increases of abdominal pressure: e.g. coughing, sneezing or laughing, Grade 2: loss of urine with lesser degrees of stress: e.g. walking or standing up, and Grade 3: loss of urine without any relation to physical activity or position, e.g. while lying in bed.
The primary end point at 12 months is a mean change in Stamey Grade from baseline of greater than or equal to -1.</description>
          <population>Intent to Treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" lower_limit="-1.33" upper_limit="-1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon’s matched pairs signed ranks test was used to determine the significance of differences between scores at follow-up compared to pre-implant.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.16</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.325</ci_lower_limit>
            <ci_upper_limit>-1.003</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incontinence Quality of Life (IQoL) Questionnaire</title>
        <description>Change on Incontinence Quality of Life (IQoL) Questionnaire from baseline to 12 months. 0 being lowest quality of life, 100 being highest quality of life.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>ACT Adjustable Continence Therapy for Women</title>
            <description>Open Label Study, patients implanted with ACT device for treatment of SUI</description>
          </group>
        </group_list>
        <measure>
          <title>Incontinence Quality of Life (IQoL) Questionnaire</title>
          <description>Change on Incontinence Quality of Life (IQoL) Questionnaire from baseline to 12 months. 0 being lowest quality of life, 100 being highest quality of life.</description>
          <population>Intent to Treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.63" spread="29.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incontinence Impact Questionnaire (IIQ-7)</title>
        <description>Incontinence Impact Questionnaire (IIQ-7) change from baseline to 12 months. Scores range from 0-100. 0 being impact from incontinence, 100 being most impacted from incontinence.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>ACT Adjustable Continence Therapy for Women</title>
            <description>Open Label Study, patients implanted with ACT device for treatment of SUI</description>
          </group>
        </group_list>
        <measure>
          <title>Incontinence Impact Questionnaire (IIQ-7)</title>
          <description>Incontinence Impact Questionnaire (IIQ-7) change from baseline to 12 months. Scores range from 0-100. 0 being impact from incontinence, 100 being most impacted from incontinence.</description>
          <population>Intent to Treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.53" spread="33.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Distress Inventory (UDI-6)</title>
        <description>Change on Urinary Distress Inventory (UDI-6) questionnaire from baseline to 12 months. 0 being not distressed, 100 being very distressed.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>ACT Adjustable Continence Therapy for Women</title>
            <description>Open Label Study, patients implanted with ACT device for treatment of SUI</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Distress Inventory (UDI-6)</title>
          <description>Change on Urinary Distress Inventory (UDI-6) questionnaire from baseline to 12 months. 0 being not distressed, 100 being very distressed.</description>
          <population>Intent to Treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.66" spread="24.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Incontinence Episodes Per Day (Voiding Diary)</title>
        <description>Change in Number of Incontinence Episodes Per Day from baseline to 12 months. 0 being the best.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>ACT Adjustable Continence Therapy for Women</title>
            <description>Open Label Study, patients implanted with ACT device for treatment of SUI</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incontinence Episodes Per Day (Voiding Diary)</title>
          <description>Change in Number of Incontinence Episodes Per Day from baseline to 12 months. 0 being the best.</description>
          <population>Intent to Treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Pads Changed Per Day (Voiding Diary)</title>
        <description>Change in Number of Pads Changed Per Day from baseline to 12 months. 0 pads changed a day being the best.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>ACT Adjustable Continence Therapy for Women</title>
            <description>Open Label Study, patients implanted with ACT device for treatment of SUI</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pads Changed Per Day (Voiding Diary)</title>
          <description>Change in Number of Pads Changed Per Day from baseline to 12 months. 0 pads changed a day being the best.</description>
          <population>Intent to Treat</population>
          <units>Number of Pads Changed per Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Provocative Pad Weight</title>
        <description>Change in weight of pads (gm) from baseline to 12 months. 0 gm pad weight being the best.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>ACT Adjustable Continence Therapy for Women</title>
            <description>Open Label Study, patients implanted with ACT device for treatment of SUI</description>
          </group>
        </group_list>
        <measure>
          <title>Provocative Pad Weight</title>
          <description>Change in weight of pads (gm) from baseline to 12 months. 0 gm pad weight being the best.</description>
          <population>Intent to Treat</population>
          <units>gm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.03" spread="55.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Entire Study December 2001 to November 2010 at Study Closure</time_frame>
      <desc>All adverse events were collected. Overall, although there were a large number of adverse events on the study (883) the majority were unrelated to the device (75%) or the procedure (82%) and 75% resolved with no residual effects. Of the 883 events, 270 of those events (31%) were considered device and/or procedure related.</desc>
      <group_list>
        <group group_id="E1">
          <title>ACT Adjustable Continence Therapy for Women</title>
          <description>Open Label Study, Patients implanted with ACT device</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Other (non-pelvic)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>port erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain/Discomfort</sub_title>
                <counts group_id="E1" events="70" subjects_affected="51" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Balloon Migration</sub_title>
                <description>Balloon device moves from implantation site</description>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Balloon Erosion</sub_title>
                <description>Balloon Erodes into Vagina, Urethra, or Bladder</description>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Port Migration</sub_title>
                <description>Port moves from implantation site</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Port Erosion</sub_title>
                <description>Port erodes out of implantation site</description>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <description>Implantation tools perforate the vagina, urethra, or bladder during implantation procedure</description>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Procedure Failure</sub_title>
                <description>Procedure is not able to be completed</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Other (Pelvic)</sub_title>
                <counts group_id="E1" events="118" subjects_affected="75" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Other (non-Pelvic)</sub_title>
                <counts group_id="E1" events="336" subjects_affected="112" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infected Device</sub_title>
                <description>Infection of ACT Device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Failure</sub_title>
                <description>ACT device failure</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Incontinence</sub_title>
                <description>Patient has worsening incontinence symptoms</description>
                <counts group_id="E1" events="37" subjects_affected="35" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <description>Urinary Tract Infection</description>
                <counts group_id="E1" events="165" subjects_affected="75" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Yeast Infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="31" subjects_affected="24" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Timothy Plouffe</name_or_title>
      <organization>Uromedica</organization>
      <phone>763-999-7048</phone>
      <email>tplouffe@uromedica-inc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

